IL-6 antagonists to replace systemic corticosteroids as the preferred anti-inflammatory therapy in patients with COVID-19?
作者信息
Kow Chia Siang, Zaihan Abdullah Faiz, Ramachandram Dinesh Sangarran, Hasan Syed Shahzad
机构信息
School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia; School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Subang Jaya, Selangor, Malaysia.
Department of Pharmacy, Shah Alam Hospital, Persiaran Kayangan, Seksyen 7, Shah Alam, Selangor, Malaysia.
出版信息
Cytokine. 2022 Jan;149:155730. doi: 10.1016/j.cyto.2021.155730. Epub 2021 Oct 5.
Abstract
摘要
相似文献
1
IL-6 antagonists to replace systemic corticosteroids as the preferred anti-inflammatory therapy in patients with COVID-19?白细胞介素-6拮抗剂能否取代全身用皮质类固醇，成为新冠病毒病患者首选的抗炎治疗药物？
Cytokine. 2022 Jan;149:155730. doi: 10.1016/j.cyto.2021.155730. Epub 2021 Oct 5.
2
Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis.托珠单抗、沙利鲁单抗与 COVID-19 住院患者 28 天全因死亡率的关联：一项网状荟萃分析。
PLoS One. 2022 Jul 8;17(7):e0270668. doi: 10.1371/journal.pone.0270668. eCollection 2022.
3
Early Combination of Tocilizumab and Corticosteroids: An Upgrade in Anti-inflammatory Therapy for Severe Coronavirus Disease (COVID).托珠单抗与皮质类固醇的早期联合应用：重症冠状病毒病（COVID）抗炎治疗的升级
Clin Infect Dis. 2021 May 4;72(9):1682-1683. doi: 10.1093/cid/ciaa910.
4
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.抗白细胞介素药物治疗重症 COVID-19 患者（COV-AID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):468. doi: 10.1186/s13063-020-04453-5.
5
Attenuating COVID-19 infection and inflammation: Lessons from asthma.减轻新型冠状病毒肺炎感染与炎症：哮喘带来的启示
Respirology. 2020 Dec;25(12):1233-1234. doi: 10.1111/resp.13961. Epub 2020 Oct 13.
6
[Intestinal perforation in patient with COVID-19 infection treated with tocilizumab and corticosteroids. Report of a clinical case].[接受托珠单抗和皮质类固醇治疗的COVID-19感染患者发生肠穿孔。1例临床病例报告]
Cir Esp (Engl Ed). 2021 Feb;99(2):156-157. doi: 10.1016/j.ciresp.2020.04.030. Epub 2020 Apr 29.
7
Unresolved questions about the treatment of COVID-19 with corticosteroids.关于使用皮质类固醇治疗新冠病毒病（COVID-19）的未解决问题。
Med Clin (Barc). 2021 Feb 12;156(3):143-144. doi: 10.1016/j.medcli.2020.10.010. Epub 2020 Nov 7.
8
The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis.COVID-19 感染患者中皮质类固醇治疗的比例和效果：系统评价和荟萃分析。
PLoS One. 2021 Apr 21;16(4):e0249481. doi: 10.1371/journal.pone.0249481. eCollection 2021.
9
The role of IL-6 and IL-6 blockade in COVID-19.IL-6 及其阻断在 COVID-19 中的作用。
Expert Rev Clin Immunol. 2021 Jun;17(6):601-618. doi: 10.1080/1744666X.2021.1919086. Epub 2021 May 27.
10
Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.早期识别 COVID-19 细胞因子风暴并使用阿那白滞素或托珠单抗治疗。
Int J Infect Dis. 2020 Oct;99:291-297. doi: 10.1016/j.ijid.2020.07.081. Epub 2020 Aug 6.
引用本文的文献
1
Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure.新冠病毒病合并心力衰竭患者的糖皮质激素治疗
Rev Clin Esp (Barc). 2022 May;222(5):309-310. doi: 10.1016/j.rceng.2021.11.002. Epub 2022 Jan 31.
2
[Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure].[新型冠状病毒肺炎合并心力衰竭患者的糖皮质激素治疗]
Rev Clin Esp. 2022 May;222(5):309-310. doi: 10.1016/j.rce.2021.11.002. Epub 2021 Nov 20.
本文引用的文献
1
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.COVID-19 住院患者中使用白细胞介素 6 拮抗剂与死亡率的关系：一项荟萃分析。
JAMA. 2021 Aug 10;326(6):499-518. doi: 10.1001/jama.2021.11330.
2
The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review.瑞德西韦治疗中重度 COVID-19 患者的效果：一项系统评价。
Expert Rev Anti Infect Ther. 2022 Feb;20(2):211-229. doi: 10.1080/14787210.2021.1949984. Epub 2021 Jul 29.
3
Accelerating the Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: A Risk of Combining Dexamethasone and Tocilizumab for Severe Coronavirus Disease 2019.加速严重急性呼吸综合征冠状病毒 2 的进化：将地塞米松和托珠单抗联合用于严重 2019 冠状病毒病的风险。
J Infect Dis. 2021 Sep 17;224(6):934-937. doi: 10.1093/infdis/jiab328.
4
Tocilizumab in COVID-19: The Cerrahpaşa-PREDICT score.托珠单抗治疗 COVID-19：Cerrahpaşa-PREDICT 评分。
J Infect Chemother. 2021 Sep;27(9):1329-1335. doi: 10.1016/j.jiac.2021.05.007. Epub 2021 May 12.
5
Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One.皮质类固醇联合托珠单抗治疗新冠肺炎：两者联用优于单用。
Chest. 2021 May;159(5):2108-2109. doi: 10.1016/j.chest.2020.11.073.
6
Does methylprednisolone reduce the mortality risk in hospitalized COVID-19 patients? A meta-analysis of randomized control trials.甲泼尼龙是否降低住院 COVID-19 患者的死亡风险？一项随机对照试验的荟萃分析。
Expert Rev Respir Med. 2021 Aug;15(8):1049-1055. doi: 10.1080/17476348.2021.1925546. Epub 2021 Jul 2.
7
The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials.托珠单抗对 COVID-19 住院患者死亡率的影响：一项随机对照试验的荟萃分析。
Eur J Clin Pharmacol. 2021 Aug;77(8):1089-1094. doi: 10.1007/s00228-021-03087-z. Epub 2021 Feb 2.
8
Corticosteroid-related In-Hospital Hyperglycemia: Does It Negate Mortality Benefits in Coronavirus Disease 2019?皮质类固醇相关的院内高血糖：它是否会抵消2019冠状病毒病的死亡率益处？
Clin Infect Dis. 2021 Nov 2;73(9):e2848-e2849. doi: 10.1093/cid/ciaa1423.
9
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.COVID-19 重症患者全身使用皮质类固醇与死亡率的关联：一项荟萃分析。
JAMA. 2020 Oct 6;324(13):1330-1341. doi: 10.1001/jama.2020.17023.
Zotero 插件